Abstract 112: Low Plasma Low-density Lipoprotein Cholesterol Level as a Risk Factor for Cancer in Patients With Newly Diagnosed Coronary Artery Disease

2016 ◽  
Vol 36 (suppl_1) ◽  
Author(s):  
Xiaofeng Chen ◽  
Jianjun Jiang ◽  
Haihua Yang ◽  
Bing Wang ◽  
Yinsheng Xue ◽  
...  
Keyword(s):  
Risk Factors ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Stent Implantation ◽  
Low Density Lipoprotein ◽  
Cell Cancer ◽  
Density Lipoprotein ◽  
Low Density ◽  
Newly Diagnosed ◽  
Artery Disease

Background and Objective: Coronary artery disease (CAD) and cancer are the leading causes of death worldwide and share some risk factors, such as aging and smoking. Concurrence of CAD and cancers makes diagnosis and treatment more clinical challenging. In patients who need stent implantation followed by dual antiplatelet therapy, fatal perioperative complications such as bleeding and stent thrombosis may occur. There is no data regarding the prevalence and risk factors of cancer in patients with CAD. This study investigated the cancer prevalence and risk factors in patients with newly diagnosed CAD. Methods and Results: Three thousand and one hundred and eighty six consecutive patients with newly angiographically documented CAD were prospectively enrolled between January 2009 and March 2015. Serum levels of tumor markers, including carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen125, carbohydrate antigen 153, carbohydrate antigen199, squamous cell cancer antigen, and prostate-specific antigen, were measured. Diagnosis of cancer was confirmed by pathology or imaging with ultrasound, computed tomography or magnetic resonance. The prevalence of cancer in CAD patients was 1.1% (35 out of 3186), involving the in gastroenterogical, respiratory, endocrine and exocrine, urinary and hematopoietic systems. Among these cancer patients, 17 patients had stent implantation, with 7 AMI patients undergoing emergency PCI. Multivariate analysis revealed that, in addition to male gender and advanced age, lower plasma low-density lipoprotein (LDL) cholesterol levels were independently associated with the occurrence of cancer in CAD patients (P<0.01). Conclusion: Cancers occur in 1.1% of patients with CAD. Low LDL levels may increase the risk for cancers in the CAD patients. Further large scale studies are needed to validate this association.

scholarly journals Investigation of Serum Oxidized Low-Density Lipoprotein IgG Levels in Patients with Angiographically Defined Coronary Artery Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Mohsen Moohebati ◽  
Vahid Kabirirad ◽  
Majid Ghayour-Mobarhan ◽  
Habibollah Esmaily ◽  
Shima Tavallaie ◽  
...  
Keyword(s):  
Risk Factors ◽  
Coronary Artery Disease ◽  
Cardiovascular Risk ◽  
Coronary Artery ◽  
Cardiovascular Risk Factors ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density ◽  
Significant Difference ◽  
Artery Disease

It has been suggested that antioxidized low-density lipoprotein (anti-oxLDL) antibodies play a role in the pathogenesis of atherosclerosis. The aim of this study was to measure serum ox-LDL IgG levels in 31 patients with angiographically defined coronary artery disease (CAD) (≥50% stenosis in at least one major coronary artery; CAD+group) and compare these levels with those of 32 subjects with <50% coronary stenosis (CAD−group) and 24 healthy age- and sex-matched controls using ELISA. We did not find any significant difference between CAD+, CAD−, and control groups in regard to oxLDL IgG levels (P=0.83). Serum oxLDL IgG levels did not differ between 1VD (one vessel disease), 2VD (2 vessels disease), and 3VD (3 vessels disease) subgroups of CAD+patients (P=0.20). Serum anti-oxLDL titers were only significantly correlated with LDL-C in the CAD+group (P<0.05) and waist and hip circumference (P<0.05andP<0.01, resp.) in the CAD−group. In stepwise regression analysis, none of the conventional cardiovascular risk factors was associated with serum ox-LDL IgG levels. The present results suggest that serum levels of ox-LDL IgG are neither associated with the presence and severity of CAD nor with the conventional cardiovascular risk factors.

scholarly journals Baseline Low-Density-Lipoprotein Cholesterol Modifies the Risk of All-Cause Death Associated With Elevated Lipoprotein(a) in Coronary Artery Disease Patients

2022 ◽  
Vol 8 ◽  
Author(s):  
Younan Yao ◽  
Jin Liu ◽  
Bo Wang ◽  
Ziyou Zhou ◽  
Xiaozhao Lu ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density ◽  
Low Density Lipoprotein Cholesterol ◽  
Penalized Spline ◽  
All Cause Mortality ◽  
Artery Disease

Background: The prognostic value of elevated lipoprotein(a) [Lp(a)] in coronary artery disease (CAD) patients is inconsistent in previous studies, and whether such value changes at different low-density-lipoprotein cholesterol (LDL-C) levels is unclear.Methods and Findings: CAD patients treated with statin therapy from January 2007 to December 2018 in the Guangdong Provincial People's Hospital (NCT04407936) were consecutively enrolled. Individuals were categorized according to the baseline LDL-C at cut-off of 70 and 100 mg/dL. The primary outcome was 5-year all-cause death. Multivariate Cox proportional models and penalized spline analyses were used to evaluate the association between Lp(a) and all-cause mortality. Among 30,908 patients, the mean age was 63.1 ± 10.7 years, and 76.7% were men. A total of 2,383 (7.7%) patients died at 5-year follow-up. Compared with Lp(a) &lt;50 mg/dL, Lp(a) ≥ 50 mg/dL predicted higher all-cause mortality (multivariable adjusted HR = 1.19, 95% CI 1.07–1.31) in the total cohort. However, when analyzed within each LDL-C category, there was no significant association between Lp(a) ≥ 50 mg/dL and higher all-cause mortality unless the baseline LDL-C was ≥ 100 mg/dL (HR = 1.19, 95% CI 1.04–1.36). The results from penalized spline analyses were robust.Conclusions: In statin-treated CAD patients, elevated Lp(a) was associated with increased risks of all-cause death, and such an association was modified by the baseline LDL-C levels. Patients with Lp(a) ≥ 50 mg/dL had higher long-term risks of all-cause death compared with those with Lp(a) &lt;50 mg/dL only when their baseline LDL-C was ≥ 100 mg/dL.

Sign in / Sign up

Export Citation Format

Share Document